[Rhythm of expression of BCL-2 protein of MA13/C mammaryadenocarcinoma bearing-mice].
We previously demonstrated a circadian rhythm in response to docetaxel chemotherapy in C3H/HeN mice bearing MA13/C mammary adenocarcinoma. We investigated the relation between this rhythm and the expression of BCL-2 in bone marrow and in tumor tissues. A circadian rhythm characterized BCL-2 expression in the bone marrow, which was hardly modified in tumor-bearing animals. BCL-2 acrophase coincided with the time of highest docetaxel tolerability and efficacy in this model. This suggests that BCL-2 protects the bone marrow from the drug toxicity, especially during the light phase.
Granda
Teresa G
TG
Inserm E 0354, Hôpital Paul-Brousse, Villejuif, France.
Filipski
Elisabeth
E
Vrignaud
P
P
Bissery
M C
MC
Lévi
Francis
F
D000230:Adenocarcinoma / Q000235:genetics / Q000503:physiopathology* / Q000556:secondary; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D001853:Bone Marrow / Q000378:metabolism; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000517:prevention & control; D019454:Chronotherapy; D002940:Circadian Rhythm / Q000235:genetics*; D000077143:Docetaxel; D015972:Gene Expression Regulation, Neoplastic / Q000502:physiology*; D019254:Genes, bcl-2; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D051379:Mice; D008809:Mice, Inbred C3H; D009363:Neoplasm Proteins / Q000096:biosynthesis* / Q000235:genetics; D009368:Neoplasm Transplantation; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000096:biosynthesis*; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity
D000972:Antineoplastic Agents, Phytogenic; D009363:Neoplasm Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D043823:Taxoids; D000077143:Docetaxel